Skip to main content

PERSPECTIVE article

Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1545787

Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing

Provisionally accepted
Christof Wedemeyer Christof Wedemeyer 1Martin Peters Martin Peters 1GRAHAM JONES GRAHAM JONES 2*
  • 1 Novartis (Switzerland), Basel, Switzerland
  • 2 Tufts Medical Center, Boston, United States

The final, formatted version of the article will be published soon.

    Despite its known correlations with risk of cardiovascular disease, awareness and testing for Lipoprotein (a) lags that of other serological markers with estimates that less than 1% of the US population have undergone screening. Herein we outline how digital tools framed around motivational models (COM-B and SEM), might help increase likelihood of patients seeking Lp(a) testing as part of their managed care. Furthermore, we highlight how recent trends in prescription of GLP-1 receptor antagonists are serving to motivate patients to manage biomarkers related to T2D and obesity, which are also relevant in cardiovascular disease. Capitalizing on this trend to stimulate interest in Lp(a) management could have near term consequence, and with disease modifying therapies in development ultimately improve outcomes in cardiovascular disease.

    Keywords: Awareness, Digital support, Patient awareness, Motivational tools, Lipoprotein a, prevention

    Received: 15 Dec 2024; Accepted: 24 Jan 2025.

    Copyright: © 2025 Wedemeyer, Peters and JONES. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: GRAHAM JONES, Tufts Medical Center, Boston, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.